Integration	O
of	O
Serum	B:C0036825
Protein	I:C0036825
Biomarker	B:C0005516
and	O
Tumor	B:C0027651
Associated	O
Autoantibody	B:C0004358
Expression	B:C1171362
Data	O
Increases	O
the	O
Ability	O
of	O
a	O
Blood	B:C1510438
-	I:C1510438
Based	I:C1510438
Proteomic	I:C1510438
Assay	I:C1510438
to	O
Identify	O
Breast	B:C0006142
Cancer	I:C0006142
.	O

Despite	O
significant	O
advances	O
in	O
breast	B:C1134632
imaging	I:C1134632
,	O
the	O
ability	O
to	O
accurately	O
detect	B:C0442726
Breast	B:C0006142
Cancer	I:C0006142
(	O
Breast	B:C0006142
Cancer	I:C0006142
)	O
remains	O
a	O
challenge	O
.	O

With	O
the	O
discovery	O
of	O
key	B:C0005516
biomarkers	I:C0005516
and	O
protein	B:C3463810
signatures	I:C3463810
for	O
Breast	B:C0006142
Cancer	I:C0006142
,	O
proteomic	B:C1327760
technologies	O
are	O
currently	O
poised	O
to	O
serve	O
as	O
an	O
ideal	O
diagnostic	B:C3161326
adjunct	I:C3161326
to	O
imaging	B:C0011923
.	O

Research	B:C0681814
studies	I:C0681814
have	O
shown	O
that	O
breast	B:C0006142
tumors	I:C0006142
are	O
associated	O
with	O
systemic	O
changes	O
in	O
levels	O
of	O
both	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
(	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
)	O
and	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
(	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
)	O
.	O

However	O
,	O
the	O
independent	O
contribution	O
of	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
and	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
expression	B:C1171362
data	O
for	O
identifying	O
Breast	B:C0006142
Cancer	I:C0006142
relative	O
to	O
a	O
combinatorial	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
and	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
approach	O
has	O
not	O
been	O
fully	O
investigated	O
.	O

This	O
study	B:C2603343
evaluates	B:C0220825
these	O
contributions	O
using	O
a	O
retrospective	B:C2985505
cohort	I:C2985505
of	O
pre	O
-	O
biopsy	B:C0005558
serum	B:C1550100
samples	I:C1550100
with	O
known	O
clinical	B:C0456984
outcomes	I:C0456984
collected	O
from	O
a	O
single	O
site	B:C1515974
,	O
thus	O
minimizing	O
potential	O
site	O
-	O
to	O
-	O
site	O
variation	B:C1846356
and	O
enabling	O
direct	O
assessment	O
of	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
and	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
contributions	O
to	O
identify	O
Breast	B:C0006142
Cancer	I:C0006142
.	O

All	O
serum	B:C1550100
samples	I:C1550100
(	O
n	O
=	O
210	O
)	O
were	O
collected	O
prior	O
to	O
biopsy	B:C0005558
.	O

These	O
specimens	O
were	O
obtained	O
from	O
18	O
participants	B:C0679646
with	O
no	B:C1276755
evidence	I:C1276755
of	I:C1276755
breast	I:C1276755
disease	I:C1276755
(	O
ND	B:C1276755
)	O
,	O
92	O
participants	B:C0679646
diagnosed	B:C0011900
with	O
Benign	B:C0016034
Breast	I:C0016034
Disease	I:C0016034
(	O
Benign	B:C0016034
Breast	I:C0016034
Disease	I:C0016034
)	O
and	O
100	O
participants	B:C0679646
diagnosed	B:C0011900
with	O
Breast	B:C0006142
Cancer	I:C0006142
,	O
including	O
DCIS	B:C0007124
.	O

All	O
Benign	B:C0016034
Breast	I:C0016034
Disease	I:C0016034
and	O
Breast	B:C0006142
Cancer	I:C0006142
diagnoses	B:C0011900
were	O
based	O
on	O
pathology	B:C0030664
results	O
from	O
biopsy	B:C0005558
.	O

Statistical	B:C0026348
models	I:C0026348
were	O
developed	O
to	O
differentiate	O
Breast	B:C0006142
Cancer	I:C0006142
from	O
non-BC	O
(	O
i.e.	O
,	O
Benign	B:C0016034
Breast	I:C0016034
Disease	I:C0016034
and	O
ND	B:C1276755
)	O
using	O
expression	B:C1171362
data	O
from	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
alone	O
,	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
alone	O
,	O
and	O
a	O
combination	O
of	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
and	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
.	O

When	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
data	O
was	O
independently	O
used	O
for	O
modeling	B:C0870071
,	O
clinical	B:C1516631
sensitivity	I:C1516631
and	O
specificity	O
for	O
detection	O
of	O
Breast	B:C0006142
Cancer	I:C0006142
were	O
74.7	O
%	O
and	O
77.0	O
%	O
,	O
respectively	O
.	O

When	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
data	O
was	O
independently	O
used	O
,	O
clinical	B:C1516631
sensitivity	I:C1516631
and	O
specificity	O
for	O
detection	B:C0442726
of	O
Breast	B:C0006142
Cancer	I:C0006142
were	O
72.2	O
%	O
and	O
70.8	O
%	O
,	O
respectively	O
.	O

When	O
modeling	B:C0870071
integrated	O
data	O
from	O
both	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
and	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
,	O
the	O
clinical	B:C1516631
sensitivity	I:C1516631
and	O
specificity	O
for	O
detection	O
of	O
Breast	B:C0006142
Cancer	I:C0006142
improved	O
to	O
81.0	O
%	O
and	O
78.8	O
%	O
,	O
respectively	O
.	O

These	O
data	O
demonstrate	O
the	O
benefit	O
of	O
the	O
integration	O
of	O
serum	B:C0005516
protein	I:C0005516
biomarkers	I:C0005516
and	O
tumor	B:C0004358
associated	I:C0004358
autoantibodies	I:C0004358
data	O
and	O
strongly	O
support	O
the	O
further	O
development	O
of	O
combinatorial	O
proteomic	O
approaches	O
for	O
detecting	O
Breast	B:C0006142
Cancer	I:C0006142
.	O

